Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated portfolio spanning immunomodulators, antibody-drug conjugates, ...

As the European Lung Cancer Congress prepares to convene in Copenhagen, BioNTech SE is shifting investor focus toward its expanding oncology portfolio. New clinical data for its antibody-drug ...

BioNTech SE will announce its financial results for the first quarter of 2025 on May 5, 2025, and will hold a conference call and webcast at 8:00 a.m. EDT (2:00 p.m. CEST) to discuss these results and ...

Germany-based biotechnology firm BioNTech SE (BNTX) on Thursday said that it intends to acquire its peer CureVac (CVAC) in an all-stock transaction. CVAC stock shot up by about 32% in pre-market ...

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb & Co. (NYSE:BMY) entered into a co-development and co-commercialization agreement. The pact focuses on BioNTech’s investigational bispecific antibody ...

BioNTech SE will release its financial results for the second quarter of 2025 on August 4, 2025, and will hold a conference call and webcast that day at 8:00 a.m. EDT to discuss these results and ...

MAINZ, Germany, September 23, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech”), alongside its artificial intelligence (“AI”) company ...

BioNTech SE (NASDAQ:BNTX) is one of the Stocks That Will Go To The Moon in 2026. On December 18, BioNTech SE (NASDAQ:BNTX) announced the closing of its acquisition of CureVac N.V. (NASDAQ:CVAC), which ...

Germany-based BioNTech (NASDAQ: BNTX) saw its U.S. listed stock enjoy a mini-pop on Wednesday, and for once this wasn't largely based on the Comirnaty COVID-19 vaccine it developed with Pfizer. Rather ...

Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated ...

Presentations showcase progress in BioNTech's late-stage lung cancer programs, reinforcing the potential of the Company's differentiated portfolio spanning immunomodulators, antibody-drug conjugates, ...